Posts

St. Jude Home Care, LLC is first US pediatric home heal...

St. Jude Children’s Research Hospital announces today that St. Jude Home Care LL...

What if cows could talk?

You may not know it, but cows share information every time they burp, moo, and c...

A statewide survey shows the digital divide narrowing i...

Statewide broadband adoption remains high with 91% of households in California e...

Tests can reveal whether an antibody can turn into a ki...

What makes a soldier switch sides? That is a really good question. Especially wh...

The surface knows what lies beneath: physicists show ho...

Just like a book can’t be judged by its cover, a material can’t always be judged...

Researchers find that using patients’ own blood, rather...

In a collaboration between the Fralin Biomedical Research Institute at VTC and C...

Study reveals a reaction at the heart of many renewable...

CAMBRIDGE, MA — A key chemical reaction — in which the movement of protons betwe...

Water as a nonlinear medium for ultrabroadband white laser

Scientists are making significant strides in the development of ultrabroadband w...

Novel drug for fatal type of heart failure proves safe ...

Pumping over 100,000 times a day, the heart is a critical muscle needed to deliv...

Enhanced photoelectrochemical water splitting with a do...

Polyimide (PI) has emerged as a promising organic photocatalyst owing to its dis...

Is soil nitrogen mineralization important in agricultur...

Soil nitrogen mineralization (Nmin) is a key process that converts organic N int...

BioNTech Allocates $20 Million to WuXi for Two Preclini...

BioNTech, the renowned German biotechnology powerhouse, has engaged in a substan...

Drug Farm candidate gains rare paediatric disease status  

Drug Farm’s ALPK1 inhibitor DF-003 is being investigated in a Phase I trial for ...

Amgen showcases exciting potential in the obesity space...

If new treatments are shown to maintain weight loss, they will become game chang...

MSD’s Keytruda wins expanded FDA combo approval in cerv...

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures ...

Basilea buys Spexis’ preclinical antibiotics programme ...

The acquired programme consists of antibiotics against gram-negative bacteria, i...